By API User
People on long-term opioid treatment can be reassured that stopping these medicines is not likely to increase their risk of suicide or fatal overdose, thanks to a major new study from the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney. The Australian-first research, based on data from 3.57 million people prescribed opioids, found … Continued
By API User
Healthcare finance executive joins Australian medical device innovator as company scales commercial operations following FDA authorization MELBOURNE, Australia & DALLAS–BUSINESS WIRE– Epiminder Limited, a pioneering medical device company developing breakthrough epilepsy monitoring technology, today announced the appointment of Mark McLellan as Chief Financial Officer. McLellan brings extensive experience in healthcare finance and strategic leadership to … Continued
By API User
Collaboration Strengthens Census Through Location-Enabled Data Sharing REDLANDS, Calif.–BUSINESS WIRE– Esri, the global leader in location intelligence, today announced the extension of its strategic partnership with the United Nations Population Fund (UNFPA) in support of the 2030 census round. Building on a successful collaboration during the 2020 census round, the partnership aims to embed geographic … Continued
By API User
October is Mental Health Month, and with new research showing 6 in 10 Australian workers have faced burnout or disengagement in 2025 – one of the highest rates in the OECD – The Story Code author Mark Jones is available for interviews and commentary. A journalist turned executive coach and speaker, Mark helps people understand why we … Continued
By API User
ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced its Burlington, MA sterile drug product facility has been named “Manufacturer of the Year” by the Massachusetts Legislative Manufacturing Caucus. The award was presented at the 10th Annual Manufacturing Awards Ceremony, held on … Continued
By API User
Hologic Stockholders to Receive $76 per Share in Cash Plus a Contingent Value Right of up to $3 per Share Payable Upon Achieving Certain Revenue Milestones Represents 46% Premium to Hologic’s Closing Price on Last Trading Day Prior to Media Reports of Possible Transaction Transaction Includes Significant Minority Investments from ADIA and GIC Transaction Will … Continued
By API User
This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression of progressive supranuclear palsy (PSP) The study is being conducted across 44 centers in the European Union, the United Kingdom, and the United States The study reinforces Ferrer’s commitment … Continued
By API User
Six early-career scientists and clinicians will receive $150,000 each to conduct research on metabolic therapies for mental health SAN MATEO, Calif.–BUSINESS WIRE– Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working to advance understanding of the connection … Continued
By API User
Media Release 21st October 2025 We need evidence-based health policy on drug use in the ACT – not political games Today’s failed attempt by the ACT Liberals to overturn recent changes to drug laws in the ACT flies in the face of sensible evidence-based policy and is completely out of step with the … Continued
By API User
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC) No dose-limiting toxicities and no treatment-related serious adverse events observed Xerostomia predominantly Grade 1 80% PSA50 response at doses ≥ 160 MBq 100% objective response rate (ORR) in … Continued
